MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors
Ying Meng, Christopher B Pople, Suganth Suppiah, Maheleth Llinas, Yuexi Huang, Arjun Sahgal, James Perry, Julia Keith, Benjamin Davidson, Clement Hamani, Yutaka Amemiya, Arun Seth, Hon Leong, Chinthaka C Heyn, Isabelle Aubert, Kullervo Hynynen, Nir Lipsman, Ying Meng, Christopher B Pople, Suganth Suppiah, Maheleth Llinas, Yuexi Huang, Arjun Sahgal, James Perry, Julia Keith, Benjamin Davidson, Clement Hamani, Yutaka Amemiya, Arun Seth, Hon Leong, Chinthaka C Heyn, Isabelle Aubert, Kullervo Hynynen, Nir Lipsman
Abstract
Background: Liquid biopsy is promising for early detection, monitoring of response, and recurrence of cancer. The blood-brain barrier (BBB) limits the shedding of biomarker, such as cell-free DNA (cfDNA), into the blood from brain tumors, and their detection by conventional assays. Transcranial MR-guided focused ultrasound (MRgFUS) can safely and transiently open the BBB, providing an opportunity for less-invasive access to brain pathology. We hypothesized that MRgFUS can enrich the signal of circulating brain-derived biomarkers to aid in liquid biopsy.
Methods: Nine patients were treated in a prospective single-arm, open-label trial to investigate serial MRgFUS and adjuvant temozolomide combination in patients with glioblastoma (NCT03616860). Blood samples were collected as an exploratory measure within the hours before and after sonication, with control samples from non-brain tumor patients undergoing BBB opening (BBBO) alone (NCT03739905).
Results: Brain regions averaging 7.8 ± 6.0 cm3 (range 0.8-23.1 cm3) were successfully treated within 111 ± 39 minutes without any serious adverse events. We found MRgFUS acutely enhanced plasma cfDNA (2.6 ± 1.2-fold, P < .01, Wilcoxon signed-rank test), neuron-derived extracellular vesicles (3.2 ± 1.9-fold, P < .01), and brain-specific protein S100b (1.4 ± 0.2-fold, P < .01). Further comparison of the cfDNA methylation profiles suggests a signature that is disease- and post-BBBO-specific, in keeping with our hypothesis. We also found cfDNA-mutant copies of isocitrate dehydrogenase 1 (IDH1) increased, although this was in only one patient known to harbor the tumor mutation.
Conclusions: This first-in-human proof-of-concept study shows MRgFUS enriches the signal of circulating brain-derived biomarkers, demonstrating the potential of the technology to support liquid biopsy for the brain.
Keywords: blood-brain barrier; brain tumor; focused ultrasound; glioblastoma; liquid biopsy.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Figures
References
- Dawson SJ, Tsui DW, Murtaza M, et al. . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–1209.
- Maheswaran S, Sequist LV, Nagrath S, et al. . Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366–377.
- Shen SY, Singhania R, Fehringer G, et al. . Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563(7732):579–583.
- Detection of glioma and prognostic subtypes by non-invasive circulating cell-free DNA methylation markers | bioRxiv. . Accessed April 29, 2020
- Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer. 2020;1(3):276–290.
- Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26–41.
- Meng Y, Hynynen K, Lipsman N. Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat Rev Neurol. 2021;17(1):7–22.
- Carpentier A, Canney M, Vignot A, et al. . Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016;8(343):343re2.
- Idbaih A, Canney M, Belin L, et al. . Safety and feasibility of repeated and transient blood-brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma. Clin Cancer Res. 2019;25(13):3793–3801.
- Mainprize T, Lipsman N, Huang Y, et al. . Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study. Sci Rep. 2019;9(1):321.
- Lipsman N, Meng Y, Bethune AJ, et al. . Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound. Nat Commun. 2018;9(1):2336.
- Abrahao A, Meng Y, Llinas M, et al. . First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat Commun. 2019;10(1):4373.
- Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A. 2006;103(31):11719–11723.
- Alkins R, Burgess A, Kerbel R, Wels WS, Hynynen K. Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. Neuro Oncol. 2016;18(7):974–981.
- Zhu L, Cheng G, Ye D, et al. . Focused ultrasound-enabled brain tumor liquid biopsy. Sci Rep. 2018;8(1):6553.
- Pacia CP, Zhu L, Yang Y, et al. . Feasibility and safety of focused ultrasound-enabled liquid biopsy in the brain of a porcine model. Sci Rep. 2020;10(1):7449.
- Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage. 2005;24(1):12–20.
- McDannold N, Vykhodtseva N, Hynynen K. Use of ultrasound pulses combined with definity for targeted blood-brain barrier disruption: a feasibility study. Ultrasound Med Biol. 2007;33(4):584–590.
- Sanchez C, Snyder MW, Tanos R, Shendure J, Thierry AR. New insights into structural features and optimal detection of circulating tumor DNA determined by single-strand DNA analysis. NPJ Genom Med. 2018;3:31.
- Mustapic M, Eitan E, Werner JK Jr, et al. . Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Front Neurosci. 2017;11:278.
- Capper D, Jones DTW, Sill M, et al. . DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469–474.
- Tateishi K, Wakimoto H, Cahill DP. IDH1 mutation and World Health Organization 2016 diagnostic criteria for adult diffuse gliomas: advances in surgical strategy. Neurosurgery. 2017;64(CN_suppl_1):134–138.
- Gutteridge A, Rathbone VM, Gibbons R, et al. . Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. Cancer Med. 2017;6(10):2194–2202.
Source: PubMed